ISO 14971:2019 - Medical Device Risk Management Foundation Free Practice Test — 30 Questions

Question 1

A manufacturer of an implantable cardiac rhythm management device is preparing for a significant software update. This update is intended to improve battery efficiency and optimize signal processing algorithms, but it does not directly alter the core pacing or defibrillation functions. According to ISO 14971:2019, under what circumstances would the manufacturer be most compelled to initiate a comprehensive re-evaluation of the entire risk management process for this device?

Accepted Answer

Upon the release of the new software version that modifies operational parameters and signal processing, necessitating a review of potential new hazards and existing risk controls.

Question 2

Following a significant software update to a Class II implantable cardiac defibrillator, which action is most critical to ensure continued compliance with ISO 14971:2019 and relevant regulatory requirements such as the EU MDR (Regulation (EU) 2017/745)?

Accepted Answer

Re-evaluate the entire risk management file, specifically focusing on the impact of the software modification on identified hazards, the effectiveness of existing risk controls, and the introduction of any new hazards or changes to the risk acceptability criteria.

Question 3

When does the established acceptability of a medical device\'s risks, as determined during the initial risk evaluation phase according to ISO 14971:2019, require formal re-assessment and potential revision?

Accepted Answer

Upon the occurrence of significant changes to the device's intended use, design, or manufacturing process, or when new information regarding the device's risks emerges during its lifecycle.

Question 4

Considering the lifecycle approach mandated by ISO 14971:2019 for medical device risk management, what is the fundamental principle governing the continuation of risk management activities after a device has been released to the market?

Accepted Answer

Risk management activities must be continuously maintained and updated throughout the entire life cycle of the medical device, including post-market phases, in response to new information.

Question 5

Following a substantial design modification to a Class II implantable cardiac pacemaker, specifically the integration of a new, more energy-efficient battery chemistry to extend operational lifespan, what is the most critical risk management action mandated by ISO 14971:2019 concerning the existing risk management file?

Accepted Answer

Conduct a thorough re-evaluation of all identified hazards and associated risks, considering the potential impact of the new battery chemistry on device performance, biocompatibility, and electromagnetic compatibility, and update the risk management file accordingly.

Question 6

A manufacturer of a diagnostic imaging device, initially intended for use in adult hospital settings, receives regulatory approval to expand its intended use to pediatric outpatient clinics. This expansion involves minor software adjustments to optimize image acquisition parameters for smaller anatomical structures and a change in the power supply unit to meet different electrical standards. What is the most appropriate action regarding the device\'s risk management file according to ISO 14971:2019?

Accepted Answer

Conduct a comprehensive review and update of the entire risk management file, including risk analysis, risk evaluation, and risk control measures, to account for the altered intended use and any new hazards or changes in risk associated with the modifications.

Question 7

Following the successful market release of a novel diagnostic imaging device, the manufacturer receives a series of post-market surveillance reports detailing an unexpected interaction between the device\'s proprietary contrast agent injector and a specific class of commonly prescribed anticoagulants. Preliminary analysis suggests a potential for increased risk of localized tissue damage at the injection site, a hazard not fully characterized during the initial risk assessment due to the rarity of this specific drug-device combination. According to the principles outlined in ISO 14971:2019, what is the most critical immediate step the manufacturer must undertake upon receiving this aggregated post-market data?

Accepted Answer

Initiate a comprehensive review of the risk management file to incorporate the new information, re-evaluate associated risks, and determine if revised risk control measures are necessary.

Question 8

A manufacturer of a diagnostic imaging system receives feedback indicating a potential for image artifacts under specific, previously uncharacterized, environmental conditions. The engineering team proposes a software update to mitigate this issue. According to the principles outlined in ISO 14971:2019, what is the most appropriate action regarding the existing risk management file for this diagnostic imaging system?

Accepted Answer

Initiate a comprehensive review of the risk management process, including re-evaluation of identified hazards, risk analysis, risk evaluation, and risk control measures, to incorporate the impact of the proposed software update.

Question 9

A medical device manufacturer identifies a hazard associated with a complex control panel, leading to a risk of unintended patient harm due to incorrect parameter selection. To address this, the engineering team redesigns the control panel with a simplified, intuitive graphical interface. Subsequently, a separate team conducts a series of simulated use studies with representative users to confirm that the new interface effectively prevents incorrect parameter inputs. Which of the following accurately categorizes these two distinct activities within the context of ISO 14971:2019?

Accepted Answer

The redesigned interface is a risk reduction measure, and the simulated use studies are verification of that measure.

Question 10

A manufacturer of an implantable cardiac rhythm management device decides to upgrade the internal power source to a new chemistry that promises a longer operational lifespan. This modification involves changes to the power management circuitry and the charging interface. According to ISO 14971:2019, what is the most appropriate action regarding the existing risk management file for this device?

Accepted Answer

Conduct a comprehensive re-evaluation of all identified hazards and hazardous situations, considering the impact of the new power source and associated circuitry changes on the device's overall safety, and update the risk management file accordingly.

Question 11

Considering the overarching principles of ISO 14971:2019, which statement best encapsulates the fundamental objective of establishing and maintaining a comprehensive risk management process for a medical device throughout its entire lifecycle, encompassing both pre-market and post-market phases?

Accepted Answer

To systematically identify, evaluate, and control risks to an acceptable level, ensuring that the benefits of the medical device outweigh the identified risks, thereby safeguarding patients and users.

Question 12

A medical device initially designed and validated for diagnostic imaging of internal structures undergoes a significant modification to enable it to deliver targeted therapeutic energy to specific tissues. This change in intended use, from passive observation to active intervention, necessitates a comprehensive review of its risk management file. What is the most appropriate action to ensure continued compliance with ISO 14971:2019 following this fundamental alteration in the device\'s function and intended application?

Accepted Answer

Conduct a complete re-evaluation of the risk management file, including hazard identification, risk analysis, risk evaluation, and verification of risk control measures for the new intended use.

Question 13

Following the successful market introduction of a novel implantable cardiac defibrillator, the manufacturer receives multiple reports from healthcare providers detailing an unexpected software anomaly that, under specific, albeit rare, operational conditions, can lead to a temporary cessation of pacing. While the device\'s primary defibrillation function remains unimpaired, this pacing interruption poses a potential risk to patients with specific underlying cardiac conditions. According to the principles outlined in ISO 14971:2019, what is the most appropriate immediate action for the manufacturer to undertake upon receiving this information?

Accepted Answer

Initiate a comprehensive review of the risk management file, specifically re-evaluating the identified hazards, risk analysis, risk evaluation, and risk control measures related to the software's pacing function, and implement necessary updates and corrective actions.

Question 14

Considering the comprehensive framework outlined in ISO 14971:2019 for medical device risk management, what is the overarching objective that guides the entire lifecycle of a device\'s risk control measures?

Accepted Answer

To ensure that the realized risks associated with the medical device are reduced to an acceptable level throughout its entire lifecycle.

Question 15

Considering the lifecycle approach mandated by ISO 14971:2019, which of the following best characterizes the essential purpose and content of the risk management file for a novel implantable cardiac defibrillator, particularly in the context of post-market surveillance and potential regulatory scrutiny under frameworks like the EU MDR?

Accepted Answer

A static repository detailing initial hazard identification and risk assessment, primarily serving as a historical record of design-phase risk controls.

Question 16

A manufacturer of a diagnostic imaging device, initially cleared for use in hospital radiology departments, discovers a potential for its application in mobile screening units operating in remote, resource-limited settings. This new intended use involves different environmental conditions, a wider range of user technical proficiencies, and potentially altered power supply stability. According to the principles of ISO 14971:2019, what is the most appropriate action the manufacturer must take regarding the device\'s risk management file before marketing for this expanded use?

Accepted Answer

Conduct a comprehensive re-evaluation of the risk management process, including hazard identification, risk analysis, risk evaluation, and the implementation of necessary risk control measures for the new intended use.

Question 17

A manufacturer of an implantable cardiac rhythm management device decides to update the device\'s firmware to incorporate a novel predictive algorithm designed to anticipate potential arrhythmias. This algorithm significantly alters how the device interprets patient cardiac signals and adjusts pacing parameters. Following the firmware update and subsequent in-vitro testing, a critical failure mode is identified where the new algorithm, under specific rare signal conditions, incorrectly interprets a benign electrical artifact as a life-threatening arrhythmia, leading to inappropriate high-energy cardioversion. Which of the following actions best reflects the requirements of ISO 14971:2019 concerning this post-market change?

Accepted Answer

Conduct a full risk re-evaluation, including hazard identification, risk analysis, risk evaluation, and implementation of new control measures for the updated firmware, before releasing it to the market.

Question 18

Considering the lifecycle approach mandated by ISO 14971:2019, which of the following best describes the primary purpose of establishing a robust feedback mechanism from post-market surveillance activities to the risk management process?

Accepted Answer

To ensure that newly identified hazards or changes in the risk profile of a medical device are systematically incorporated into the risk management file and addressed throughout its lifecycle.

Question 19

Considering the lifecycle approach mandated by ISO 14971:2019, what event most critically necessitates a comprehensive re-evaluation of the entire risk management process for an established medical device, beyond routine periodic reviews?

Accepted Answer

The introduction of a significant design modification impacting the device's core functionality or intended use.

Question 20

A manufacturer of an implantable cardiac defibrillator (ICD) receives reports from post-market surveillance indicating a statistically significant increase in lead fractures occurring after 7 years of implantation, a failure mode not previously identified as a primary concern within the initial risk assessment. This new data suggests a potential degradation mechanism under specific physiological conditions. Considering the continuous nature of risk management as mandated by ISO 14971:2019 and the need to comply with regulatory frameworks like the EU MDR\'s emphasis on lifecycle management, what is the most appropriate immediate action for the manufacturer?

Accepted Answer

Update the risk management file to include the new hazard, reassess the risk associated with lead fracture, and evaluate the effectiveness of existing risk control measures or implement new ones.

Question 21

A manufacturer of a diagnostic imaging system, initially intended for use in a hospital setting by trained radiologists, is considering expanding its market to include smaller clinics where the device might be operated by less specialized technicians. This proposed change in intended use necessitates a thorough re-evaluation of the existing risk management file. Which of the following actions is most critical to ensure continued compliance with ISO 14971:2019 and relevant regulatory frameworks like the EU Medical Device Regulation (MDR)?

Accepted Answer

Conduct a comprehensive re-analysis of all identified hazards and risks, considering the new user profile and operational environment, and update the risk management plan and report accordingly.

Question 22

Considering the lifecycle approach mandated by ISO 14971:2019, what is the primary driver for initiating a re-evaluation of a medical device\'s risk management file during the post-production phase, beyond routine scheduled reviews?

Accepted Answer

The emergence of new information indicating that the existing risk controls may no longer be adequate to manage identified hazards or that previously unrecognized hazards exist.

Question 23

Following the widespread market release of the \'CardioGuard 3000\' implantable cardiac monitor, the manufacturer receives a statistically significant increase in post-market surveillance reports detailing unexpected battery depletion events, leading to premature device failure. These reports are distinct from the initially identified failure modes documented during design and verification. What is the most appropriate immediate action for the manufacturer to take regarding their risk management process for the CardioGuard 3000, in accordance with ISO 14971:2019 principles?

Accepted Answer

Review and potentially update the risk management file, including the risk analysis and risk evaluation, to incorporate the new information regarding battery depletion and its associated risks.

Question 24

Considering the lifecycle approach mandated by ISO 14971:2019, at what specific juncture is a comprehensive review of the risk management file explicitly required to ensure compliance with the standard\'s provisions before the medical device is made available to the market?

Accepted Answer

Upon the completion of the risk management file in preparation for initial market release.

Question 25

When evaluating the acceptability of residual risk associated with a novel diagnostic imaging device intended for use in critical care settings, what is the primary determinant according to the principles outlined in ISO 14971:2019?

Accepted Answer

The residual risk is compared against the medical device's risk management policy and its established risk acceptability criteria.

Question 26

A manufacturer of an implantable cardiac rhythm management device is developing a significant software update that incorporates a novel machine learning algorithm to predict and preemptively adjust pacing parameters based on subtle physiological cues. This algorithm fundamentally alters how the device responds to patient conditions compared to its previous deterministic logic. Considering the lifecycle approach mandated by ISO 14971:2019, what is the most critical risk management activity that must be undertaken before the release of this updated device?

Accepted Answer

Conduct a thorough re-evaluation of the entire risk management file, including hazard identification, risk analysis, and risk evaluation, to account for the impact of the new machine learning algorithm on device performance and patient safety.

Question 27

Following a significant firmware update to a Class II diagnostic imaging device, which action is most critical to ensure ongoing compliance with ISO 14971:2019 and relevant global medical device regulations like the EU MDR?

Accepted Answer

Conduct a thorough review and update of the entire risk management file, specifically re-evaluating all identified hazards, risks, and risk control measures in light of the firmware modification.

Question 28

Following the implementation of a newly designed safety interlock mechanism intended to mitigate a previously identified hazard associated with a diagnostic imaging system, what is the mandatory next step in the risk management process as stipulated by ISO 14971:2019?

Accepted Answer

Re-evaluate the acceptability of the residual risk associated with the hazard.

Question 29

Following the widespread adoption of its novel neurostimulator, a medical device company receives an influx of post-market surveillance reports detailing unexpected neurological side effects not previously identified during pre-market risk assessment. These reports, originating from diverse clinical settings and patient populations, suggest a potential correlation between a specific stimulation parameter setting and the onset of these adverse events. According to the principles outlined in ISO 14971:2019, what is the most appropriate and compliant course of action for the manufacturer to take upon receiving and verifying this new information regarding potential hazards?

Accepted Answer

Initiate a comprehensive review of the existing risk management file, including re-evaluation of the risk analysis, risk evaluation, and risk control measures, to incorporate the newly identified hazard and its potential impact on device safety.

Question 30

A manufacturer is developing a novel diagnostic imaging device intended for use in specialized neurological procedures. The proposed intended use, which defines the specific patient population and diagnostic capabilities, is currently under review by a national regulatory authority. While awaiting this approval, the manufacturer must continue to develop the device and its associated risk management documentation. Which of the following actions best reflects the appropriate approach to risk management in this scenario, according to ISO 14971:2019?

Accepted Answer

Commence risk management activities based on the proposed intended use, meticulously documenting the conditional nature of this use and planning for subsequent updates upon regulatory clearance.

ISO 14971:2019 - Medical Device Risk Management Foundation Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 14971:2019 - Medical Device Risk Management Foundation Certification